Drugs / TNG348
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06065059 | Dec 2023 → May 2024 | BRCA1-related cancer predisposition, hereditary breast carcinoma, malignant pancreatic neoplasm, ovarian carcinoma +1 | Tango Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNG348 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06065059 ↗ |
| Action | Inhibit | “Ubiquitin Specific Peptidase 1 (USP1) inhibitor” NCT06065059 ↗ |
| Target | USP1 | “Ubiquitin Specific Peptidase 1 (USP1) inhibitor” NCT06065059 ↗ |